Gufic Biosciences

₹436.30As of Sun 8 Nov 2026, 12:00 UTC

NSE:GUFICBIOHealthcare

Country India

PE (Fwd) 63.21

TSR 10Y CAGR 22.39%

Div yield 0.02%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) (0.03)

PE TTM 68.13

TSR TTM 34.11%

Mkt cap ₹48.34B

ROIC —

SE Grade™

—

Value

Quality

Moat

—

1Y Price

Reference

₹483

10.60%

(72.41%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

9.440

Revenue₹B

—

7.792

6.906

8.067

8.198

9.440

9.814

4.92%

15.15

Revenue growth%

—

(11.36)

16.80

1.63

15.15

3.96

8.39

—

54.50

Gross margin%

—

46.01

50.87

50.58

53.41

54.50

54.65

50.87

12.77

Operating margin%

—

16.57

16.70

16.44

14.31

12.77

16.44

6.80

Net margin%

—

12.30

11.54

10.68

8.50

6.80

6.78

10.68

68.13

P/E ratio (avg)x

—

19.55

27.89

33.26

55.31

54.60

65.77

33.26

36.31

EV/EBITx

—

14.51

19.28

21.61

32.83

29.09

34.91

21.61

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

6.40

EPS₹

—

9.89

8.22

8.74

6.95

6.40

6.63

(10.29%)

—

(7.80)

EPS growth%

—

(16.84)

6.34

(20.56)

(7.80)

3.60

(12.32)

—

Bookvalue per sh₹

—

FCF per share₹

—

0.10

Dividend per sh₹

—

0.10

—

0.02

Div yield (avg)%

—

0.05

0.04

0.03

0.02

0.03

1.56

Payout ratio%

—

1.01

1.22

1.14

1.44

1.56

1.55

1.22

100.3

Shares (diluted)M

—

96.94

98.52

100.3

◌100.3

0.85%

—

Buyback yield%

—

(1.63)

(1.79)

—

◌—

(0.81)

—

D/E ratiox

—

43.75

Enterprise value₹B

—

18.74

22.23

28.65

38.53

35.06

43.75

16.96%

—

LT debt₹M

—

Peers (US$459.3M)

Cap (US$)

Evonile Pharma Limited

463.4M

—

RPG Life Sciences…

450.8M

38.23x

Aarti Drugs Limited

433.3M

17.80x

Aquestive Therapeutics…

453.7M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

3.428

8.984

Own earn%

—

Sh yield%

0.02

(0.78)

Owners

Insiders/Inst%

43.31

6.84

Short interest%

—

SBC / revenue%

0.01

Record

10Y

Profitable years

5/5

Revenue growth years

3/4

EPS growth years

1/4

Dividend streakyrs

Op margin range%

13–17

$1 testx

—

Incr. ROIC%

—

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹9.440B

4.92%

1.00×

Cost of revenue

₹4.296B

0.52%

0.84×

Operating expenses

₹3.939B

14.48%

1.42×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m